September 2, 2025 — Leads & Copy — Oncolytics Biotech Inc. (Nasdaq: ONCY) has provided an updated safety analysis of its immunotherapy, pelareorep, which has been administered to over 1,200 patients, including more than 300 with various gastrointestinal tumors.
The analysis, involving patients who received at least one intravenous dose of pelareorep, demonstrates the favorable safety profile of pelareorep in combination with numerous treatment regimens across multiple tumor types. According to Oncolytics, pelareorep represents one of the most de-risked immunotherapies that is not already approved as a treatment option in gastrointestinal tumors.
To date, over 300 gastrointestinal cancer patients across eight clinical studies have received pelareorep. It has been evaluated with new treatment regimens like modified FOLFIRINOX in metastatic pancreatic cancer and in other tumor types, including colorectal and anal cancer. Common adverse events associated with pelareorep in patients with gastrointestinal tumors are flu-like symptoms and neutropenia.
Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
Jon Patton, Director of IR & Communication, jpatton@oncolytics.ca
Mike Moyer, LifeSci Advisors, +1-617-308-4306, mmoyer@lifesciadvisors.com
Owen Blaschak, LifeSci Communications, oblaschak@lifescicomms.com
Source: Oncolytics Biotech® Inc.
